2022
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants
Mosallaei D, Hao M, Antaya RJ, Levian B, Kwong A, Cogan J, Hamilton C, Schwieger-Briel A, Tan C, Tang X, Woodley DT, Chen M. Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants. JAMA Dermatology 2022, 158: 366-374. PMID: 35234826, PMCID: PMC8892363, DOI: 10.1001/jamadermatol.2021.5992.Peer-Reviewed Original ResearchConceptsNonrandomized clinical trialIntravenous gentamicinJunctional epidermolysis bullosaNonsense variantDermal-epidermal junctionGentamicin treatmentClinical trialsEpidermolysis bullosaPopulation of patientsLaminin-332Low-dose gentamicinTotal activity scoreHome infusion servicesLong-term safetyDisease activityGentamicin therapySecondary outcomesLaminin-332 expressionPediatric patientsPrimary outcomeActivity scoreClinical outcomesAvailable therapiesNephrotoxic effectsOtotoxic effects
2004
Can Physical Activity Attenuate Aging-related Weight Loss in Older People?
Dziura J, Mendes de Leon C, Kasl S, DiPietro L. Can Physical Activity Attenuate Aging-related Weight Loss in Older People? American Journal Of Epidemiology 2004, 159: 759-767. PMID: 15051585, DOI: 10.1093/aje/kwh105.Peer-Reviewed Original ResearchConceptsPhysical activityBody weightWeight lossAge-related weight lossDisease-related weight lossOlder peopleBaseline body weightTotal activity scoreFrail older peopleEntire followActivity scoreChronic diseasesEpidemiologic studiesOlder ageWeight changeEstablished PopulationsOlder cohortRandom effects regressionNew HavenRate of agingCohortFollowYearsActivityDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply